公开(公告)号：US20160039838A1

公开(公告)日：2016-02-11

申请号：US14774702

申请日：2014-04-28

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Yingjun ZHANG ,  Bing LIU ,  Jinlei LIU ,  Jiancun ZHANG ,  Changchung CHENG

IPC: C07D491/056 ,  C07D413/12 ,  A61K31/553 ,  C07D417/12 ,  A61K31/5415 ,  C07D498/04 ,  A61K31/5383 ,  A61K31/538 ,  C07D491/048 ,  C07D495/04 ,  C07D497/04 ,  C07D401/12 ,  C07D403/12 ,  C07D491/044 ,  C07D519/00 ,  A61K31/5377 ,  A61K33/24 ,  A61K31/7008 ,  A61K39/395 ,  A61K38/21 ,  A61K31/573 ,  A61K38/12 ,  A61K31/282 ,  A61K31/704 ,  A61K31/4545 ,  A61K31/337 ,  A61K31/517

CPC classification number: C07D491/056 ,  A61K31/196 ,  A61K31/198 ,  A61K31/255 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4545 ,  A61K31/475 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/553 ,  A61K31/573 ,  A61K31/675 ,  A61K31/7008 ,  A61K31/704 ,  A61K33/24 ,  A61K38/12 ,  A61K38/212 ,  A61K39/39558 ,  A61K2039/505 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D491/044 ,  C07D491/048 ,  C07D495/04 ,  C07D497/04 ,  C07D498/04 ,  C07D519/00 ,  A61K2300/00

Abstract: Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Also provided herein are pharmaceutical compositions containing the compounds disclosed herein, and uses of the compounds or the compositions for preventing, managing, treating or lessening the severity of a proliferative disorder in a patient and for modulating the protein tyrosine kinase activity.

Abstract translation: 本文提供氨基喹唑啉化合物，其盐和用途。 化合物具有式（I）或立体异构体，几何异构体，互变异构体，N-氧化物，水合物，溶剂合物，代谢物，药学上可接受的盐或前药。 本文还提供含有本文公开的化合物的药物组合物，以及化合物或组合物用于预防，控制，治疗或减轻患者中增殖性疾病的严重性并调节蛋白酪氨酸激酶活性的用途。

公开(公告)号：US20170121323A1

公开(公告)日：2017-05-04

申请号：US15318366

申请日：2015-07-23

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Bing Liu ,  Yingjun ZHANG ,  Linlin NIE ,  Shun BAI ,  Mingyu GUAN ,  Xuke LI ,  Changchung CHENG

IPC: C07D471/04 ,  A61K31/5377 ,  C07D519/00 ,  A61K31/5383 ,  A61K45/06 ,  A61K31/519

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06 ,  C07D519/00 ,  A61K2300/00

Abstract: The invention provides compounds as CDK small-molecule inhibitors and uses thereof, the compounds can be used for treating inflammation and cell proliferation diseases. The novel compound of the invention is a powerful cyclin-dependent kinase 4 (CDK 4) or cyclin-dependent kinase-6 (CDK 6) inhibitor.

公开(公告)号：US20180030003A1

公开(公告)日：2018-02-01

申请号：US15541018

申请日：2016-02-05

Applicant: Sunshine Lake Pharma Co., Ltd.

Inventor： Xiaojun WANG ,  Xinye YANG ,  Shengqiang PAN ,  Rui GUO ,  Junwen WU ,  Yingjun ZHANG ,  Changchung CHENG

IPC: C07D261/08 ,  C07D491/147 ,  C07D491/052 ,  C07D249/06 ,  C07D413/12 ,  C07D491/044

CPC classification number: C07D261/08 ,  A61K31/42 ,  A61K31/4353 ,  A61K31/4985 ,  A61K31/519 ,  C07D249/06 ,  C07D411/12 ,  C07D413/12 ,  C07D471/04 ,  C07D491/044 ,  C07D491/052 ,  C07D491/147 ,  C07D497/04 ,  C07D498/04 ,  C07D498/14

Abstract: The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.

公开(公告)号：US20170267634A1

公开(公告)日：2017-09-21

申请号：US15504018

申请日：2015-09-11

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Yingjun ZHANG ,  Tianzhu YU ,  Bing LIU ,  Xiangyu ZHANG ,  Shiguo ZHANG ,  Changchung CHENG ,  Jiancun ZHANG

IPC: C07D209/14 ,  A61K31/454 ,  C07D401/14 ,  A61K31/4709 ,  A61K45/06 ,  C07D401/12 ,  C07D471/04 ,  A61K31/4375 ,  C07D403/12 ,  A61K31/498 ,  C07D401/04 ,  A61K31/405

CPC classification number: C07D209/14 ,  A61K31/405 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/498 ,  A61K45/06 ,  C07B2200/13 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04

Abstract: The compounds of Formula (I) which can be used as CRTH2 receptor antagonists are provided. The compounds of Formula (I) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin D2 (PGD2) at the CRTH2 receptor.